Financial News

Financial Report: Baxalta

Revenues up 7% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta 3Q Revenues: $1.6 billion (+7%) 3Q Earnings: $309 million (+26%) YTD Revenues: $4.4 billion (+3%) YTD Earnings: $861 million (-11%) Comments: Hematology revenues were $935 million in the quarter, up 10% driven by heightened demand for ADVATE and FEIBA. Immunology sales were $626 million, up 13% with continued HYQVIA sales growth. BioTherapuetics sales were $191 million, up 7%. R&D expenses were $286 million, down 8%....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters